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Objectives: Xanthorrhizol, isolated from the methanol extract of Curcuma xanthorrhiza Roxb., was
investigated for its anticandidal activity using six Candida species.
Methods: The in vitro susceptibility tests for xanthorrhizol were carried out in terms of MIC and minimal
fungicidal concentration (MFC) using the NCCLS M27-A2 broth microdilution method. Time–kill curves
were determined to assess the correlation between MIC and fungicidal activity of xanthorrhizol at con-
centrations ranging from 0 MIC to 4· MIC.
Results: All Candida species showed susceptibility to xanthorrhizol in the MIC range 1.0–15.0 mg/L for
Candida albicans, 1.0–10mg/L forCandida glabrata, 2.0–8.0 mg/L forCandida guilliermondii, 2.5–7.5mg/L
forCandida krusei, 2.5–25mg/L forCandida parapsilosis and 2.0–8.0mg/L forCandida tropicalis. Time–kill
curves demonstrated that xanthorrhizol was able to kill the Candida strains with MFCs of 20 mg/mL,
15 mg/mL, 12.5 mg/mL, 10 mg/L, 30 mg/mL and 10 mg/L for C. albicans, C. glabrata, C. guilliermondii,
C. krusei, C. parapsilosis and C. tropicalis, respectively.
Conclusions: The potent anticandidal activity of xanthorrhizol may support the use of C. xanthorriza
for the treatment of candidiasis.
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Introduction
Candida species are now recognized as a significant cause of
hospital-acquired infection. Candida albicans is the organism
most often associated with serious fungal infection and it is
showing increased resistance to traditional antifungal agents.1
Recently, non-C. albicans species, such as Candida glabrata,
Candida guilliermondii, Candida krusei, Candida parapsilosis
and Candida tropicalis, have also shown dramatic increases in
fungal infections and antifungal resistance.2
The development of resistance in known fungal pathogens and
emergence of new fungal pathogens intrinsically resistant to the
currently available antibiotics demonstrate the urgent importance
of identifying novel antifungal agents. The antifungal effect of
essential oils of many plants and their specific anticandidal activity
are well established.3 Curcuma xanthorrhiza Roxb., commonly
known as Javanese turmeric, has been traditionally used in
South-East Asian countries for food and medicinal purposes.
Xanthorrhizol, isolated from C. xanthorrhiza, has been reported
to possess anticariogenic activity against Streptococcus mutans.4
In the present research, we found that xanthorrhizol exhibited anti-
fungal activity against C. albicans, C. glabrata, C. guilliermondii,
C.krusei,C.parapsilosisandC. tropicalis. Toourknowledge, this is
the first report showing that xanthorrhizol possesses anticandidal
activity against pathogenic non-C. albicans species.
Materials and methods
Candida isolates, growth conditions and inoculum
The reference Candida species (C. albicans, C. glabrata, C. guil-
liermondii, C. krusei, C. parapsilosis and C. tropicalis) used in this
study were all obtained from the American Type Culture Collection
(Rockville, MD, USA). Clinical Candida isolates were obtained from
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The Research Institute of Bacterial Resistance, College of Medicine,
Yonsei University, Korea. The clinical isolates were from body fluid,
blood, urine, sputum and genitals of the patients. The species were
identified by conventional methods or using Vitex YBC cards
(bioMe´rieux, Marcy l’E´toile, France), according to the manufacturer’s
instructions. All clinical Candida isolates were susceptible to
fluconazole and voriconazole. The strains were cultured in Sabour-
aud dextrose broth (SDB) or on Sabouraud dextrose agar (SDA)
(Difco) for 48 h at 35C. A standardized inoculum (a McFarland
standard) for each isolate was 5 · 106 cfu/mL.5
Anticandidal agents
Xanthorrhizol was isolated as the pure form from the ethylacetate
fraction of the methanol extract of C. xanthorrhiza according to the
method of Hwang et al.4 Xanthorrhizol was dissolved in 10%
dimethylsulfoxide (DMSO) to obtain 1 g/L stock solutions.
DMSO at 10% was found not to kill the Candida. Amphotericin
B, purchased from Sigma Chemical Co. (St Louis, MO, USA), was
dissolved in sterile distilled water to obtain 1 g/L stock solution. The
concentrations of individual antifungal agents ranged as follows:
xanthorrhizol, 10–1000 mg/L; amphotericin B, 1–75 mg/L.
In vitro susceptibility tests
In vitro susceptibility tests were performed to evaluate MICs and
minimal fungicidal concentrations (MFCs) using the method
described in the guidelines of NCCLS M27-A2.5 Briefly, MICs
were determined for all species with the adjusted inoculum suspen-
sion of 5 · 106 cfu/mL by diluting the suspension 1:100 with MOPS-
buffered RPMI 1640 medium to give a final inoculum concentration
of 5 · 104 cfu/mL. Individual antifungal agents were diluted 1:10 in
MOPS-buffered RPMI 1640 medium containing 5 · 104 cfu/mL
inoculum, yielding an initial inoculum of 4.5 · 103 cfu/mL. The
final concentration of individual antifungal agents ranged as follows:
xanthorrhizol, 1–100 mg/L; amphotericin B, 0.1–7.5 mg/L. A 200 mL
aliquot of each suspension was placed in 96-well round-bottomed
microtitration plates. The plates were incubated at 35C, and end-
points were read visually after 48 h. MFCs were determined for each
anticandidal agent/Candida species/medium combination as outlined
for MICs by removing the medium from each well showing no
visible growth and subculturing onto SDA plates. The plates were
incubated at 35C until growth was seen in the growth control plates.
Time–kill curves
Time–kill assays were performed in standard MOPS-buffered RPMI
1640.5 Before the tests were performed, the Candida species were
subcultured at least twice and grown for 24 h at 35C on SDA plates.
The adjusted inoculum suspension of 5 · 106 cfu/mL was diluted
1:10 in MOPS-buffered RPMI 1640 medium to give a final inoculum
concentration of 5 · 105 cfu/mL. Each concentration of xanthorrhizol
was diluted 1:10 in MOPS-buffered RPMI 1640 medium containing
5 · 105 cfu/mL. This procedure yielded an initial inoculum of 4.5 ·
105 cfu/mL. Final concentrations of xanthorrhizol were 0·MIC, 0.5·
MIC, MIC, 2· MIC and 4· MIC for each Candida species. Cultures
(5 mL final volume) were incubated at 35C with agitation (200 rpm).
At pre-determined time points (0, 2, 4, 8, 12, 24 and 48 h) 100 mL
aliquots were removed and transferred to Eppendorf tubes, centri-
fuged (3900 g at 4C for 1 min) and rinsed twice with 0.9 mL of
sterile distilled water to obtain xanthorrhizol-free cells. Pellets were
suspended in 100 mL of sterile distilled water and serially diluted. An
appropriate volume (100, 40 or 20 mL, depending on the dilution and
the concentration of xanthorrhizol) was spread onto SDA plates and
incubated at 35C for 48 h or more (until the colonies were seen on
the plates) to determine the numbers of cfu/mL.
Results
MICs and MFCs of xanthorrhizol compared with those of ampho-
tericin B are summarized in Table 1. All species were susceptible
to xanthorrhizol. Interestingly, there were three strains of clinical
C. albicans and one strain each of clinical C. glabrata and clini-
cal C. parapsilosis that were not killed by more than 20 mg/L
amphotericin B, but the strains were killed by xanthorrhizol, at
5.0–10.0 mg/L for clinical C. albicans, 5.0 mg/L for clinical C.
glabrata and 7.5 mg/L for clinical C. parapsilosis.
The killing activity of xanthorrhizol for each species is rep-
resented in Figure 1. The fungicidal activity of xanthorrhizol was
fast acting against all Candida tested; the reduction in the number
of cfu/mL was >3 log units (99.9%). The fungicidal endpoints for
C. albicans and C. parapsilosis were reached after 48 h of
incubation at 4·MIC, while those for C. guilliermondii, C. krusei
and C. tropicalis were reached after 12 h, and that for C. glabrata
was reached after 24 h, at 4· MIC. The strongest fungicidal
activity of xanthorrhizol was observed for C. guilliermondi, C.
krusei and C. tropicalis. The fungicidal endpoint of C. guillier-
mondii, C. krusei and C. tropicalis was reached after 12 h at 4·
MIC and after 24 h at 2· MIC. These data demonstrated that the
ability to kill Candida species is dependent on the concentration
of xanthorrhizol and the species.
Discussion
In this research, we used MOPS-buffered RPMI 1640 medium for
measuring the MICs of amphotericin B and xanthorrhizol. The
results showed that MICs of amphotericin are high, particularly
for C. parapsilosis. A broth microdilution technique using RPMI
1640 is suitable for most antifungals except for amphotericin B,
as apparent resistance to this drug is not always detected in RPMI
1640. MOPS-buffered RPMI 1640 is not an ideal medium for
measuring the MICs of amphotericin.5
Generally, MICs and MFCs of amphotericin B against Can-
dida species are in good agreement with previous reports.2,6 The
isolates with reduced susceptibility to amphotericin B may also
exhibit reduced susceptibility to xanthorrhizol. There was no
previous report for xanthorrhizol against pathogenic non-C. albi-
cans species. In the present study xanthorrhizol has been shown
to possess powerful in vitro activity against a broad range of
distantly related Candida species. An anticandidal which has
broad-spectrum activity against non-C. albicans species may
have clinical applications. Snydman7 reported that the spectrum
of invasive fungal infections is changing and rising with the
frequencies of infections due to non-C. albicans species.
Among the six species of Candida used in this study,
C. guilliermondii, C. krusei and C. tropicalis were the most
susceptible to xanthorrhizol followed by C. glabrata, C. albicans
and C. parapsilosis. Knowledge of the in vitro pharmacodynamic
characteristics of C. guilliermondii is still poor and limited to
amphotericin B.8 C. glabrata infection is second or third in fre-
quency after C. albicans and is associated with a high mortality
rate in at-risk hospitalized patients. However, its epidemiology,
pathogenesis, treatment and antifungal resistance are poorly
understood.7 Moreover, compared with other Candida species,
especially with C. albicans, higher levels of all azole antifungals
Rukayadi et al.
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are required for comparable activity against C. glabrata isolates.9
Our study showed that C. glabrata was more susceptible to
xanthorrhizol compared with C. albicans. This result suggested
that xanthorrhizol may be effective in treating C. glabrata infec-
tion. C. parapsilosis is the most frequently isolated yeast species
from hospital patients and the most common non-C. albicans
species causing infection in cancer patients.10 Our results also
demonstrated that xanthorrhizol has the ability to inhibit and to
kill C. parapsilosis in vitro.
Overall, xanthorrhizol may be potentially valuable as a natural
compound for fungal infections, even though its anticandidal
activity is weaker than that of amphotericin B against six species
of Candida. However, the clinical applications of xanthorrhizol
are challenging to interpret in this study due to a lack of
Candida albicans
0
1
2
3
4
5
6
7
Lo
g 
cf
u/
m
L
Candida glabrata
0
1
2
3
4
5
6
7
Lo
g 
cf
u/
m
L
0 16 24 32 40 48
Time (h)
8 0 16 24 32 40 48
Time (h)
8
Candida guilliermondii
0
1
2
3
4
5
6
7
0 16 24 32 40 48
Time (h)
Lo
g 
cf
u/
m
L
8
Candida krusei
0
1
2
3
4
5
6
7
0 16 24 32 40 48
Time (h)
Lo
g 
cf
u/
m
L
8
Candida parapsilosis
(a)
(c)
(e)
(b)
(d)
(f)
0
1
2
3
4
5
6
7
0 16 24 32 40 48
Time (h)
Lo
g 
cf
u/
m
L
8
Candida tropicalis
0
1
2
3
4
5
6
7
0 16 24 32 40 48
Time (h)
Lo
g 
cf
u/
m
L
8
Figure 1. Representative time–kill plots for Candida species following exposure to xanthorrhizol at 0·MIC (filled diamonds), 0.5·MIC (filled squares), 1·MIC
(filled triangles), 2·MIC (open squares) and 4·MIC (open triangles) after endpoint (48 h). (a)C. albicansATCC10231 (0, 7.5, 15, 30 and 60mg/L); (b)C. glabrata
ATCC 50044 (0, 5, 10, 20 and 40 mg/L); (c) C. guilliermondii ATCC 9058 (0, 4, 8, 16 and 32 mg/L); (d) C. krusei ATCC 32196 (0, 3.75, 7.5, 15 and 30 mg/L);
(e)C. parapsilosisATCC22019 (0, 12.5, 25, 50 and 100mg/L); and (f)C. tropicalisATCC28142 (0, 4, 8, 16 and 32mg/L). Values given in the brackets after species
are 0· MIC, 1· MIC, 2· MIC and 4· MIC, respectively.
Xanthorrhizol is an anticandidal
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pharmacokinetic and safety studies. Unanswered concerns exist
about the in vivo efficacy and toxicity of xanthorrhixol. Future
research towards these objectives, based on animal models, may
resolve these issues.
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Table 1. In vitro anticandidal activity of xanthorrhizol against Candida species
Drug/Candida spp.
No. of isolates
MIC (mg/L) MFC (mg/L)
tested for MIC/MFC MIC50 MIC90 range MFC50 MFC90 range
Xanthorrhizol
C. albicans ATCC 12 5.0 10.0 2.5–15 8.0 8.0 5.0–20.0
C. albicans (clinical) 18 2.5 4.0 1.0–5.0 6.0 6.0 5.0–10.0
C. albicans (clinical)a 3 2.5 4.0 2.0–5.0 5.0 5.0 5.0–10.0
C. glabrata (ATCC) 4 5.0 8.0 4.0–10 10.0 10.0 7.5–15.0
C. glabrata (clinical) 11 2.5 4.0 1.0–5.0 4.0 4.0 2.5–7.5
C. glabrata (clinical)a 1 2.5 5.0
C. guilliermondii (ATCC) 4 4.0 6.0 2.0–8.0 7.5 7.5 5.0–12.5
C. guilliermondii (clinical) 2 2.5 and 4.0 5.0 and 7.5
C. krusei (ATCC) 4 4.0 7.5 2.5–7.5 5.0 5.0 4.0 and 10.0
C. parapsilosis (ATCC) 4 12.5 17.5 10.0–25 20.0 20.0 15–30
C. parapsilosis (clinical) 19 10 15 7.5–20 20.0 20.0 15–30
C. parapsilosis (clinical)a 1 5.0 7.5
C. tropicalis (ATCC) 4 4.0 6.0 2.0–8.0 5.0 5.0 4.0–10.0
Amphotericin B
C. albicans ATCC 12 1.5 2.5 1.0–4.0 2.5 5.0 1.5–7.5
C. albicans (clinical) 18 1.0 2.0 0.5–2.5 2.5 4.0 1.0–5.0
C. albicans (clinical)a 3 > 15 > 20
C. glabrata (ATCC) 4 2.0 4.0 1.5–5.0 4.0 6.0 2.0–8.0
C. glabrata (clinical) 11 1.0 2.0 0.5–2.5 2.5 4.0 1.0–5.0
C. glabrata (clinical)a 1 > 15 > 20
C. guilliermondii (ATCC) 4 4.0 7.5 2.5–7.5 8.0 10.0 7.5–12.5
C. guilliermondii (clinical) 2 2.5 and 5.0 2.5 and 5.0
C. krusei (ATCC) 4 2.0 4.0 1.0–5.0 4.0 7.5 2.0 and 7.5
C. parapsilosis (ATCC) 4 5.0 7.5 4.0–125 7.5 10.0 5.0–15
C. parapsilosis (clinical) 19 5.0 7.5 7.5–20 7.5 10.0 5.0–15
C. parapsilosis (clinical)a 1 >15 >20
C. tropicalis (ATCC) 4 2.5 4.0 2.0–8.0 4.0 5.0 2.5–7.5
aIsolates resistant to amphotericin B.
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